Revenue for the six months ended January 31, 2008 was $73.3 million compared with $45.4 million in the same period of 2007. Net income for the current quarter was up 84% to $3.5 million or $0.05 per share, compared with $1.9 million or $0.03 per share, for the same period of 2007. Net income for the first six months of fiscal 2008 was $7.8 million or $0.11 per share, compared with $6.4 million or $0.10 per share in the same period of fiscal 2007.
John Langstaff, president and CEO of Cangene, said: “Cangene posted solid financial results and furthered certain key objectives during this quarter, despite the fact that we did not make additional product deliveries relating to the US government stockpiling contracts during this quarter. In addition, we once again demonstrated our regulatory capabilities in the quarter by achieving licensure of the convenient liquid formulation of WinRho SDF for the Canadian market and approval of our recombinant human growth hormone, Accretropin, in the US.”